| Biotechnology feed | All feeds
Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news.
Join 66,000+ biotechnology and pharma industry... FierceBiotech: Jan 26 2010 2:04AM Matching: uloric Find similar documents
11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues,... KOTA Territory News: Jan 16 2010 8:04PM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ --Ardea... KOTA Territory News: Jan 16 2010 8:02PM Matching: uloric Find similar documents
11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S.
and Europe, a drug that resolves tophi in less than one year would become... SmartBrief: Jan 12 2010 1:12AM Matching: uloric Find similar documents
and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic... News-Medical.Net: Jan 12 2010 11:10AM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ --Ardea... Montana's News Station: Jan 10 2010 10:59AM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ -- Ardea... Pharma Live: Jan 8 2010 1:19AM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well... Pharmacy Choice: Jan 7 2010 10:37PM Matching: uloric Find similar documents
7 SAN DIEGO, Jan.
7 ... Biz Journals: Jan 7 2010 3:54PM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ -- (Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive... BioSpace: Jan 7 2010 3:28PM Matching: uloric Find similar documents
7 /PRNewswire-FirstCall/ --Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as... Red Orbit: Jan 7 2010 3:27PM Matching: uloric Find similar documents
7 /PRwire-FirstCall/ --Ardea Biosciences, Inc.
today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as... Genetic Engineering News: Jan 7 2010 3:03PM Matching: uloric Find similar documents
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as... Yahoo! Canada: Jan 7 2010 2:54PM Matching: uloric Find similar documents
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as... Therapeutics Daily: Jan 7 2010 2:13PM Matching: uloric Find similar documents
(RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as... Houston Chronicle: Jan 7 2010 2:10PM Matching: uloric Find similar documents
7 ... Atlanta Business Chronicle: Jan 7 2010 2:00PM Matching: uloric Find similar documents
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as... Street Insider: Jan 7 2010 1:56PM Matching: uloric Find similar documents
7 --Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the... Earthtimes.org: Jan 7 2010 1:54PM Matching: uloric Find similar documents
Companies: Related Quotes {'s' : 'rdea','k' ... PR Newswire via Yahoo!: Jan 7 2010 1:46PM Matching: uloric Find similar documents
(Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as... NewsBlaze: Jan 7 2010 1:37PM Matching: uloric Find similar documents
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright 1997-2009 - BioPortfolio Limited.
